GE Healthcare Life Sciences has expanded production capabilities at its Pasching, Austria facility for sterile liquids.
GE Healthcare Life Sciences announced on April 12, 2016 that its European manufacturing and distribution site in Pasching, Austria for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids, and cell-culture media. The company has also launched a rapid production service for prototype cell culture media and buffers, according to a press announcement.
According to GE Healthcare Life Sciences, the Pasching facility works with biopharmaceutical companies in more than 40 countries across Europe, Africa, and the Middle East. The facility now offers rapid response production services, which enable production of small volumes of prototype cell-culture media and buffers within five days of ordering.
GE’s additional production capacity at Pasching has been developed over two years, with an investment of $4.3 million. The site is also a production and distribution center for Europe, with more than 300,000 individual product items shipped through the site per year.
Source: GE Healthcare Life Sciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.